nach oben

Erschienen in:

11.02.2014 | Fortbildung

Pharmakologische Therapieoptionen in der psychiatrischen Versorgung

Autistische Störungen vom Kindes- bis ins Erwachsenenalter

verfasst von: Dr. med. Eftichia Duketis

Erschienen in: DNP – Die Neurologie & Psychiatrie | Ausgabe 2/2014

Einloggen, um Zugang zu erhalten

Zusammenfassung

Zur Behandlung der Kernsymptome bei Patienten mit autistischen Störungen sind verhaltenstherapeutisch-orientierte Verfahren und Trainings die Methoden der Wahl. Psychopharmakologische Interventionen sind über die gesamte Lebensspanne abzuwägen bei schweren Stereotypien, (auto-) aggressiven Verhaltensweisen, ADHS-Symptomen sowie komorbiden psychiatrischen Störungen. Allerdings sind in Deutschland alle medikamentösen Behandlungen von Autismus-assoziierten Symptomen als individueller Heilversuch einzustufen, da hier noch kein Medikament spezifisch für diese Indikationsgebiete bei Autismus zugelassen ist.

WHO. The ICD-10 classification of mental and behavioral disorders: clinical descriptions and diagnostic guidelines. Geneva: World Health Organisation; 1992.

Baird G, Simonoff E, Pickles A, Chandler S, Loucas T, Meldrum D, et al. Prevalence of disorders of the autism spectrum in a population cohort of children in South Thames: the Special Needs and Autism Project (SNAP). Lancet. 2006;368(9531):210–215.PubMedCrossRef

Fombonne E. Epidemiology of pervasive developmental disorders. Pediatric research. 2009;65(6):591–598.PubMedCrossRef

Brugha TS, McManus S, Bankart J, Scott F, Purdon S, Smith J, et al. Epidemiology of autism spectrum disorders in adults in the community in England. Arch Gen Psychiatry. 2011;68(5):459–465.PubMedCrossRef

Mesibov GB, Handlan S. Adolescents and Adults with Autism. In: Cohen DJ, Volkmar FR, editors. Handbook of Autism and Developmental Disorders. New York: Wiley; 1997. p. 309–322.

Simonoff E, Pickles A, Charman T, Chandler S, Loucas T, Baird G. Psychiatric disorders in children with autism spectrum disorders: prevalence, comorbidity, and associated factors in a population-derived sample. Journal of the American Academy of Child and Adolescent Psychiatry. 2008;47(8):921–929.PubMedCrossRef

Leyfer OT, Folstein SE, Bacalman S, Davis NO, Dinh E, Morgan J, et al. Comorbid psychiatric disorders in children with autism: interview development and rates of disorders. J Autism Dev Disord. 2006;36(7):849–861.PubMedCrossRef

Mazzone L, Ruta L, Reale L. Psychiatric comorbidities in asperger syndrome and high functioning autism: diagnostic challenges. Annals of general psychiatry. 2012;11(1):16.PubMedCentralPubMedCrossRef

Mandell DS, Morales KH, Marcus SC, Stahmer AC, Doshi J, Polsky DE. Psychotropic medication use among Medicaid-enrolled children with autism spectrum disorders. Pediatrics. 2008;121(3):e441–448.CrossRef

10.

Bachmann CJ, Manthey T, Kamp-Becker I, Glaeske G, Hoffmann F. Psychopharmacological treatment in children and adolescents with autism spectrum disorders in Germany. Research in developmental disabilities. 2013;34(9):2551–2563.PubMedCrossRef

11.

AACAP AAoCAP. Practice parameter on the use of psychotropic medication in children and adolescents. Journal of the American Academy of Child and Adolescent Psychiatry. 2009;48(9):961–973.CrossRef

12.

Matson JL, Hess JA. Psychotropic drug efficacy and side effects for persons with autism spectrum disorders. Research in Autism Spectrum Disorders. 2011;51(1):230–236.CrossRef

13.

Lecavalier L, Leone S, Wiltz J. The impact of behaviour problems on caregiver stress in young people with autism spectrum disorders. Journal of intellectual disability research: JIDR. 2006;50(Pt 3):172–183.PubMedCrossRef

14.

Matson JL, Neal D, Fodstad JC, Hess JA. The relation of social behaviours and challenging behaviours in infants and toddlers with Autism Spectrum Disorders. Developmental neurorehabilitation. 2010;13(3):164–169.PubMedCrossRef

15.

Parikh MS, Kolevzon A, Hollander E. Psychopharmacology of aggression in children and adolescents with autism: a critical review of efficacy and tolerability. Journal of child and adolescent psychopharmacology. 2008;18(2):157–178.PubMedCrossRef

16.

Erickson CA, Posey DJ, Stigler KA, McDougle CJ. Pharmacologic treatment of autism and related disorders. Pediatric annals. 2007;36(9):575–585.PubMed

17.

Esbensen AJ, Greenberg JS, Seltzer MM, Aman MG. A longitudinal investigation of psychotropic and non-psychotropic medication use among adolescents and adults with autism spectrum disorders. J Autism Dev Disord. 2009;39(9):1339–1349.PubMedCentralPubMedCrossRef

18.

Kent JM, Kushner S, Ning X, Karcher K, Ness S, Aman M, et al. Risperidone dosing in children and adolescents with autistic disorder: a double-blind, placebo-controlled study. J Autism Dev Disord. 2013;43(8):1773–1783.PubMedCrossRef

19.

Marcus RN, Owen R, Kamen L, Manos G, McQuade RD, Carson WH, et al. placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. Journal of the American Academy of Child and Adolescent Psychiatry. 2009;48(11):1110–1119.PubMedCrossRef

20.

McCracken JT, McGough J, Shah B, Cronin P, Hong D, Aman MG, et al. Risperidone in children with autism and serious behavioral problems. The New England journal of medicine. 2002;347(5):314–321.PubMedCrossRef

21.

McDougle CJ, Scahill L, Aman MG, McCracken JT, Tierney E, Davies M, et al. Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. The American journal of psychiatry. 2005;162(6):1142–1148.PubMedCrossRef

22.

Owen R, Sikich L, Marcus RN, Corey-Lisle P, Manos G, McQuade RD, et al. Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics. 2009;124(6):1533–1540.PubMedCrossRef

23.

Pandina GJ, Bossie CA, Youssef E, Zhu Y, Dunbar F. Risperidone improves behavioral symptoms in children with autism in a randomized, double-blind, placebo-controlled trial. J Autism Dev Disord. 2007;37(2):367–373.PubMedCrossRef

24.

Shea S, Turgay A, Carroll A, Schulz M, Orlik H, Smith I, et al. Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics. 2004;114(5):e634–641.CrossRef

25.

Varni JW, Handen BL, Corey-Lisle PK, Guo Z, Manos G, Ammerman DK, et al. Effect of aripiprazole 2 to 15 mg/d on health-related quality of life in the treatment of irritability associated with autistic disorder in children: a post hoc analysis of two controlled trials. Clinical therapeutics. 2012;34(4):980–992.PubMedCrossRef

26.

Hellings JA, Zarcone JR, Reese RM, Valdovinos MG, Marquis JG, Fleming KK, et al. A crossover study of risperidone in children, adolescents and adults with mental retardation. J Autism Dev Disord. 2006;36(3):401–411.PubMedCrossRef

27.

McDougle CJ, Holmes JP, Carlson DC, Pelton GH, Cohen DJ, Price LH. A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. Arch Gen Psychiatry. 1998;55(7):633–641.PubMedCrossRef

28.

Aman MG, Kasper W, Manos G, Mathew S, Marcus R, Owen R, et al. Line-item analysis of the Aberrant Behavior Checklist: results from two studies of aripiprazole in the treatment of irritability associated with autistic disorder. Journal of child and adolescent psychopharmacology. 2010;20(5):415–422.PubMedCrossRef

29.

Aman MG, McDougle CJ, Scahill L, Handen B, Arnold LE, Johnson C, et al. Medication and parent training in children with pervasive developmental disorders and serious behavior problems: results from a randomized clinical trial. Journal of the American Academy of Child and Adolescent Psychiatry. 2009;48(12):1143–1154.PubMedCrossRef

30.

De Hert M, Dobbelaere M, Sheridan EM, Cohen D, Correll CU. Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur Psychiatry. 2011;26(3):144–158.PubMedCrossRef

31.

McKenzie ME, Roswell-Harris D. A controlled trial of prothipendyl (tolnate) in mentally subnormal patients. Br J Psychiatry. 1966;112(482):95–100.PubMedCrossRef

32.

van Hemert JC. Pipamperone (Dipiperon, R3345) in troublesome mental retardates: a double-blind placebo controlled cross-over study with long-term follow-up. Acta psychiatrica Scandinavica. 1975;52(4):237–245.PubMedCrossRef

33.

Freitag CM. Diagnostik und Therapie von autistischen Störungen im Kleinkindes- und Vorschulalter. Kinder- und Jugendmedizin. 2010(10):106–114.

34.

Hollander E, Tracy KA, Swann AC, Coccaro EF, McElroy SL, Wozniak P, et al. Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology. 2003;28(6):1186–1197.

35.

Hellings JA, Weckbaugh M, Nickel EJ, Cain SE, Zarcone JR, Reese RM, et al. A double-blind, placebo-controlled study of valproate for aggression in youth with pervasive developmental disorders. Journal of child and adolescent psychopharmacology. 2005;15(4):682–692.PubMedCrossRef

36.

Hollander E, Chaplin W, Soorya L, Wasserman S, Novotny S, Rusoff J, et al. Divalproex sodium vs placebo for the treatment of irritability in children and adolescents with autism spectrum disorders. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology. 2010;35(4):990–998.CrossRef

37.

Rezaei V, Mohammadi MR, Ghanizadeh A, Sahraian A, Tabrizi M, Rezazadeh SA, et al. Double-blind, placebo-controlled trial of risperidone plus topiramate in children with autistic disorder. Progress in neuro-psychopharmacology & biological psychiatry. 2010;34(7):1269–1272.CrossRef

38.

Symons FJ, Thompson A, Rodriguez MC. Self-injurious behavior and the efficacy of naltrexone treatment: a quantitative synthesis. Mental retardation and developmental disabilities research reviews. 2004;10(3):193–200.PubMedCrossRef

39.

Campbell M, Anderson LT, Small AM, Adams P, Gonzalez NM, Ernst M. Naltrexone in autistic children: behavioral symptoms and attentional learning. Journal of the American Academy of Child and Adolescent Psychiatry. 1993;32(6):1283–1291.PubMedCrossRef

40.

Sinzig J, Walter D, Doepfner M. Attention deficit/hyperactivity disorder in children and adolescents with autism spectrum disorder: symptom or syndrome? Journal of attention disorders. 2009;13(2):117–126.PubMedCrossRef

41.

van der Meer JM, Oerlemans AM, van Steijn DJ, Lappenschaar MG, de Sonneville LM, Buitelaar JK, et al. Are autism spectrum disorder and attention-deficit/hyperactivity disorder different manifestations of one overarching disorder? Cognitive and symptom evidence from a clinical and population-based sample. Journal of the American Academy of Child and Adolescent Psychiatry. 2012;51(11):1160–1172 e3.PubMedCrossRef

42.

Holtmann M, Bolte S, Poustka F. Attention deficit hyperactivity disorder symptoms in pervasive developmental disorders: association with autistic behavior domains and coexisting psychopathology. Psychopathology. 2007;40(3):172–177.PubMedCrossRef

43.

Research Units on Pediatric Psychopharmacology Autism. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry. 2005;62(11):1266–1274.CrossRef

44.

Arnold LE, Aman MG, Cook AM, Witwer AN, Hall KL, Thompson S, et al. Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial. Journal of the American Academy of Child and Adolescent Psychiatry. 2006;45(10):1196–1205.PubMedCrossRef

45.

King BH, Hollander E, Sikich L, McCracken JT, Scahill L, Bregman JD, et al. Lack of efficacy of citalopram in children with autism spectrum disorders and high levels of repetitive behavior: citalopram ineffective in children with autism. Arch Gen Psychiatry. 2009;66(6):583–590.PubMedCrossRef

46.

Hollander E, Soorya L, Chaplin W, Anagnostou E, Taylor BP, Ferretti CJ, et al. A double-blind placebo-controlled trial of fluoxetine for repetitive behaviors and global severity in adult autism spectrum disorders. The American journal of psychiatry. 2012;169(3):292–299.PubMedCrossRef

47.

McDougle CJ, Naylor ST, Cohen DJ, Volkmar FR, Heninger GR, Price LH. A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry. 1996;53(11):1001–1008.PubMedCrossRef

48.

Poustka L, Banaschewski T, Poustka F. Psychopharmakologie autistischer Störungen. Der Nervenarzt. 2011;82(5):582–589.PubMedCrossRef

49.

Elvins R, Green J. Pharmacological management of core and comorbid symptoms in autism spectrum disorder. Advances in psychiatric treatment. 2010;16:349–360.CrossRef

Titel: Pharmakologische Therapieoptionen in der psychiatrischen Versorgung
Autistische Störungen vom Kindes- bis ins Erwachsenenalter
verfasst von: Dr. med. Eftichia Duketis
Publikationsdatum: 11.02.2014
Verlag: Urban & Vogel
Erschienen in: DNP – Die Neurologie & Psychiatrie / Ausgabe 2/2014
Print ISSN: 2731-8168
Elektronische ISSN: 2731-8176
DOI: https://doi.org/10.1007/s15202-013-0577-9

Neu in den Fachgebieten Neurologie und Psychiatrie

16.04.2024 | Maligne primäre ZNS-Tumoren | Nachrichten

Springer Medizin

Pharmakologische Therapieoptionen in der psychiatrischen Versorgung

Autistische Störungen vom Kindes- bis ins Erwachsenenalter

Zusammenfassung

Neu in den Fachgebieten Neurologie und Psychiatrie

Manche Gestagene können das Risiko für Meningeome erhöhen

Vitiligo: Prävalenz steigt und viele Erkrankte werden spät behandelt

Perinatale PTBS: Signifikanter Anstieg der Diagnoserate

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Springer Medizin

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 2/2014

Zum Diktat das Smartphone zücken

Bereitschaftsdienst: MVZ entscheidet selbst

MS-Innovationspreise — heute Forschung, bald schon Praxis?

ADHS im Erwachsenenalter — Mode oder reale Diagnose?

Gute Studiendaten zum RLS

rTMS als Erhaltungstherapie?

Neu in den Fachgebieten Neurologie und Psychiatrie

Manche Gestagene können das Risiko für Meningeome erhöhen

Vitiligo: Prävalenz steigt und viele Erkrankte werden spät behandelt

Perinatale PTBS: Signifikanter Anstieg der Diagnoserate

Wie toxische Männlichkeit der Gesundheit von Männern schadet